SANTA BARBARA, CA--(Marketwired - Mar 26, 2014) - USDM Life Sciences, a leading global regulatory consulting firm in the life sciences industry, is pleased to announce Jay Crowley, Vice President of the Unique Device Identification Practice, will discuss FDA UDI regulations at the Global GS1 Healthcare Conference in Seoul, South Korea. Crowley is scheduled to speak at 10:30 on Tuesday, April 1st.
The Global GS1 Healthcare Conference is an opportunity for healthcare leaders to discuss worldwide efforts to improve patient safety, supply chain security and efficiency. Crowley will discuss the latest UDI compliance challenges medical device manufacturers face in the United States. Class III medical devices in the U.S. must carry a Unique Device Identifier by September 24, 2014.
"I look forward to continuing to work with the international medical device community on avoiding compliance challenges during the UDI implementation process," said Crowley. "This is a critical time of change for medical device manufacturers, I want to do everything I can to make sure their UDI adoption process is straightforward and successful."
As Vice President of the UDI Practice at USDM Life Sciences, Crowley helps medical device manufacturers achieve regulatory compliance as well as internal benefits and competitive advantage with UDI implementation.
Crowley held various positions over nearly 27 years at FDA. Most recently, he was Senior Advisor for Patient Safety, in FDA's Center for Devices and Radiological Health. Crowley had primary responsibility for the development and implementation of FDA's Unique Device Identification System.
The Global GS1 Healthcare Conference is at the Millennium Hilton Hotel in Seoul, South Korea April 1-3.
About USDM Life Sciences:
USDM Life Sciences is a leading global regulatory consulting firm providing compliance, validation, qualification, quality, auditing and information technology services via project teams and staff augmentation to our clients in the medical device, biotechnology, biologics, diagnostics and pharmaceutical industries. USDM Life Sciences has more than 14 years of experience supplying our clients in the life science industry with compliance services during each phase of their drug and product development cycle while partnering with best of breed organizations to help companies simplify, unify and optimize their business and compliance objectives. For more information, please visit www.usdm.com.